Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy

OPEN ACCESS

Articles

Page Path
HOME > Clin Endosc > Ahead-of print articles > Article
Review Endoscopic ultrasound-guided tissue acquisition as a gateway to precision oncology in pancreatic cancer: current evidence and evolving clinical utility
Sung Woo Koorcid, Seung Bae Yoonorcid

DOI: https://doi.org/10.5946/ce.2025.431
Published online: May 20, 2026

Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Correspondence: Seung Bae Yoon Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 1021 Tongil-ro, Eunpyeong-gu, Seoul 03312, Korea E-mail: sbyoon@catholic.ac.kr
• Received: November 30, 2025   • Revised: December 29, 2025   • Accepted: February 28, 2026

© 2026 Korean Society of Gastrointestinal Endoscopy

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 2,418 Views
  • 226 Download
  • 1 Web of Science
  • 1 Crossref
  • Comprehensive genomic profiling (CGP) is an important component of precision oncology in pancreatic ductal adenocarcinoma (PDAC), a malignancy with limited therapeutic options and poor overall survival. Endoscopic ultrasound (EUS)-guided tissue acquisition is the primary means of obtaining specimens for next-generation sequencing (NGS), offering high diagnostic accuracy and a favorable safety profile. Recent studies and meta-analytic data have shown that the success rate of NGS using EUS-derived samples is approximately 84%, although sequencing performance is influenced by needle characteristics, specimen type, preprocessing methods, and platform-specific DNA requirements. While the superiority of either fine-needle aspiration or fine-needle biopsy has not been definitively established, 22-gauge or larger needles may enhance tissue adequacy when technically feasible. Major genomic alterations, such as KRAS, TP53, CDKN2A, and SMAD4, have been consistently identified using EUS-derived specimens, with more than 80% concordance compared to surgical tissue. Actionable mutations, including homologous recombination repair gene defects, were found in approximately 18% of patients, supporting the clinical value of CGP in guiding therapy. Emerging biomarkers, including KRAS subtype, tumor mutational burden, microsatellite instability, and variant allele frequency, may further refine individualized treatment strategies. Continued optimization of EUS-based sampling and processing will facilitate CGP integration into PDAC management.
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive gastrointestinal cancer with few effective treatment options and poor long-term survival rates. Most patients are diagnosed at a stage when curative therapy is no longer possible, and even modern chemotherapy regimens—such as FOLFIRINOX or gemcitabine plus nab-paclitaxel—have achieved only modest improvements.1,2 Consequently, the overall 5-year survival rate is still approximately 10%. In recent years, several studies have shown that therapies guided by germline or somatic genomic alterations may provide clinical benefits for selected patients.3-5 Therefore, current guidelines recommend comprehensive genomic profiling (CGP) in PDAC to better understand tumor biology and support precision-based treatment decisions.6
Next-generation sequencing (NGS) is a practical and powerful method for detecting clinically relevant molecular changes in PDAC. Because adequate tissue is essential for sequencing, obtaining high-quality samples is a critical step in the testing process. Endoscopic ultrasound-guided tissue acquisition (EUS-TA) is the standard method used to sample pancreatic tumors, owing to its safety profile and strong diagnostic performance. Recent prospective studies have reported that EUS-TA achieves sensitivity rates >80% for solid pancreatic masses with very low complication rates.7,8 In addition to routine cytology and histology, EUS-derived samples enable ancillary studies, including immunohistochemistry and advanced molecular analyses.9 Earlier work focused mainly on detecting KRAS mutations to aid diagnosis, but the emergence of precision oncology has expanded the scope of genomic testing to include a wide set of actionable targets, making EUS-TA a key step in therapeutic planning as well. Despite these advantages, EUS-TA may yield limited tissue, which remains a major challenge for successful NGS. Several procedural and technical factors, including needle design, specimen type, processing methods, and minimum DNA requirements, directly influence sequencing outcomes. Another important issue is tumor heterogeneity because small EUS-derived samples may not always capture the complete genomic landscape of PDAC.
The authors recently conducted and published a systematic review and meta-analysis, evaluating the feasibility and utility of EUS-TA for CGP in PDAC and identifying parameters associated with sequencing success.10 Drawing upon accumulated evidence from prior studies and a comprehensive synthesis of the literature through meta-analytic review, this narrative review aims to provide an endoscopy-focused perspective on practical considerations regarding NGS in PDAC. We herein outline the key factors that endoscopists should consider during EUS-TA for CGP and highlight the critical elements for interpreting NGS results in clinical practice.
One of the earliest investigations evaluating the feasibility of EUS-TA for NGS was published in 2013.11 This retrospective analysis included 23 pancreatic tumors, of which 18 were PDACs. Tissue sampling was performed using a 19-gauge fine-needle aspiration (FNA) needle, and genomic DNA was isolated from unstained, formalin-fixed, paraffin-embedded (FFPE) specimens. A comprehensive 409-gene panel was used for molecular profiling. In a subset of five patients, the authors directly compared the genomic results obtained from EUS-FNA specimens with those derived from matched surgical tissue, and observed several clinically relevant findings. Sequencing was successful in all samples, demonstrating a 100% analytical completion rate despite limited tissue volume. Among the 18 PDAC cases, KRAS mutations were detected in 83% of patients, which is consistent with the known molecular characteristics of PDAC. Notably, in the five paired cases, complete genomic concordance was observed across the 20 identified alterations between the EUS-FNA and surgical specimens. This observation provided early evidence that EUS-derived tissue can capture the essential somatic mutation profile of PDAC, supporting its utility as a reliable substrate for CGP. Since then, numerous clinical and research studies have assessed the efficacy of EUS-TA for CGP. Although this technique has high diagnostic accuracy, obtaining adequate tissue for broader molecular analysis remains a major challenge. Needle type and gauge markedly influence specimen yield, and pre-analytic factors, such as processing methods, fixation, and minimum DNA input for NGS, also affect sequencing success. These considerations underscore the need for optimized sampling and laboratory workflows when EUS-derived specimens are used for CGP in PDAC.
In a recent meta-analysis, the pooled sequencing success rate across 19 studies was 83.9%.10 Most reports demonstrated satisfactory yields exceeding 80%; however, a few studies, primarily from Japan, showed markedly lower rates close to 50%. These discrepancies resulted in substantial heterogeneity in the pooled estimates. A key factor contributing to the lower yields in these studies was the use of the OncoGuide platform, a sequencing system approved in Japan that requires higher tumor cellularity and >200 ng of DNA input.12-14 In contrast, other platforms used in international studies were able to generate valid sequencing results with DNA quantities as low as 10 ng.15-17 Platforms such as OncoGuide offer potential advantages, including more CGP and robust assessment of biomarkers such as tumor mutational burden (TMB) and microsatellite instability (MSI); however, their relatively higher minimum DNA input requirements may limit feasibility in real-world EUS-TA settings, where tissue quantity and tumor cellularity are often constrained. In this clinical context, CGP platforms with lower minimum DNA requirements may be more promising for routine EUS-TA-based analyses. However, in the absence of direct head-to-head comparisons, these considerations should be interpreted as practical implications rather than evidence of platform superiority. To provide an integrated overview of the available evidence, the key methodological features and sequencing outcomes of prospective investigations assessing EUS-guided NGS in PDAC are summarized in Table 1.12,17-24
Beyond the choice of sequencing platform and minimum DNA input required, several additional factors may influence the success of NGS. Needle characteristics, including needle type (FNA or fine-needle biopsy, FNB) and gauge (19-, 22-, or 25-gauge), can affect tissue yield and the proportion of tumor cells obtained. The specimen format, whether cytological or histological, as well as pre-analytic processing methods, including fresh handling, FFPE, or liquid-based cytology, may further contribute to variations in sequencing performance. Because technical parameters are integral to endoscopic practice, considerable attention has been directed toward understanding how needle choice and procedure-related factors influence the adequacy of samples for downstream molecular testing. The following section provides a more detailed examination of these endoscopic determinants and their implications for NGS quality.
The comparative performance of FNA vs. FNB needles in the context of molecular testing have been variably reported. Some investigations have indicated that FNB needles may be advantageous, as they generally obtain larger and more architecturally preserved core specimens, which facilitate immunohistochemical analysis and downstream genomic testing.13,25 FNB samples are also associated with higher DNA yields in some studies.26,27 Conversely, another study suggested potential benefits of FNA, citing the higher cellularity often observed in aspirated material.16 Moreover, FNB specimens may contain more fibrotic stroma, which can dilute tumor cellularity and potentially compromise sequencing quality. Taken together, the existing evidence is heterogeneous and no definitive consensus has been reached regarding the superiority of one needle type over the other in NGS applications. In the meta-analysis, five studies directly compared FNA and FNB needles. Although FNB demonstrated a modest trend toward superior performance, the pooled results showed no statistically significant difference in sequencing yield between the two needle types.13-16,25
The question of which needle gauge offers the greatest advantage for obtaining specimens suitable for genomic analysis remains an important area of clinical interest. Although 25-gauge needles typically provide adequate material for conventional cytological diagnosis, CGP often requires a larger tissue volume and higher DNA yield, leading to the assumption that larger-caliber needles such as 19-gauge needles may be more effective. However, in practice, the increased stiffness of 19-gauge needles can restrict maneuverability, particularly when sampling lesions in the pancreatic head or tumors embedded within dense fibrotic tissue. These technical limitations may counterbalance the theoretical benefits of larger needles. To date, only one study has demonstrated superior sequencing outcomes with 22- or 19-gauge needles compared to 25-gauge needles.15 In addition, two studies conducted direct comparisons between 19-gauge and 22-gauge needles, and demonstrated superior sequencing yields with the 19-gauge needle.13,14 However, these results should be interpreted with caution, as both studies employed sequencing platforms requiring DNA inputs exceeding 200 ng. Therefore, the apparent advantage of a larger-caliber needle may reflect platform-specific requirements rather than true performance differences. Therefore, these findings may not be generalizable to NGS systems with lower DNA thresholds, and the broader applicability of this observation remains uncertain.
The influence of the number of needle passes on molecular adequacy was also evaluated. In a randomized trial using a standardized technique with a 22-gauge Franseen-tip needle, no significant differences were observed in DNA or RNA yield, or in overall sample adequacy, when comparing two versus three passes.28 Accordingly, the investigators concluded that two dedicated passes with a 22-gauge Franseen-tip needle were sufficient to obtain specimens of adequate quality for CGP, and that additional passes did not confer further benefit.
In addition, the pooled meta-analysis showed that neither the specimen type (cytological vs. histological) nor the preprocessing method (FFPE, fresh-frozen preparation, or liquid-based cytology), had a substantial effect on sequencing performance. Across these categories, the sequencing success rate consistently exceeded 80%, suggesting that EUS-derived samples are broadly reliable for CGP regardless of specimen format or processing technique.10 Although none of the included studies specifically evaluated the impact of tumor size, lesion location, endoscopist experience, or the use of rapid on-site evaluation of NGS performance, these factors are known to affect the diagnostic yield of EUS-TA and may therefore indirectly influence the feasibility and success of NGS analyses. The principal endoscopic and technical parameters that influence NGS yield in EUS-TA are delineated in Table 2.
When examining the genomic landscape of PDAC, four major driver mutations—KRAS, TP53, CDKN2A, and SMAD4—were found to predominate and collectively define the molecular profile of the disease. In the meta-analysis, KRAS alterations were consistently reported across all 23 studies, yielding a high aggregate mutation rate of approximately 86%, which aligned with the established predominance of KRAS-driven oncogenesis in PDAC. The pooled prevalence of other key driver mutations was lower but still clinically meaningful, with TP53 detected in 63%, SMAD4 in 22%, and CDKN2A in 18% of the cases. Furthermore, seven studies directly compared the CGP results obtained from EUS-derived specimens with those from matched surgical samples to assess molecular concordance. The pooled concordance rate was 81.6%, indicating that EUS-TA is generally capable of capturing core genomic alterations present in surgical specimens. This level of agreement reinforces the reliability of EUS-obtained samples for molecular profiling, and supports their use in precision oncology workflows for patients with PDAC. Meanwhile, when these results were compared with mutation profiles derived from large surgical cohorts, EUS-based analyses tended to show slightly lower detection rates for several key alterations.29 This discrepancy is likely attributable to the inherent sampling limitations of EUS-derived materials, including restricted tissue volume, lower tumor cellularity, and a higher risk of false-negative results in small or suboptimal specimens. Such factors may partially explain the modest reduction in mutation detection relative to that in surgically resected tissue.
In recent years, genomic profiling has become increasingly important in PDAC, driven by the growing need to tailor therapies to individual molecular features. Several potentially actionable alterations have also been identified in PDAC, most notably, mutations involving genes associated with homologous recombination repair, including BRCA1, BRCA2, PALB2, and ATM. These molecular defects are clinically relevant, as affected patients may derive therapeutic benefit from platinum-based chemotherapy regimens such as FOLFIRINOX and, in selected cases, from poly ADP-ribose polymerase inhibitors such as olaparib.3,30 Additional targetable alterations, although less common, include BRAF V600E, which is typically observed in KRAS wild-type tumors and is amenable to BRAF-directed therapy such as vemurafenib.31 The KRAS G12C mutation also warrants attention, as it represents a newly targetable subset with emerging agents such as sotorasib and adagrasib.32 Overall, the prevalence of potentially actionable mutations reached 18% in this meta-analysis, a rate that is highly consistent with the 17% reported in an international cohort comprising 3,594 PDAC cases.33 In our analysis, the reported prevalence of actionable mutations appeared to be higher in Eastern than in Western studies (22.4% vs. 13.6%); however, given the heterogeneity in definitions of actionable alterations and the limited sample sizes, definitive conclusions regarding racial or geographic differences cannot be drawn.
TMB, defined as the total number of somatic mutations per megabase of tumor DNA, has emerged as a potential biomarker of immunotherapy responses. Tumors with a high TMB—commonly defined as ≥10 mutations per megabase—tend to exhibit an increased neoantigen load and may have enhanced sensitivity to immune checkpoint inhibitors (ICIs). However, in PDAC, high TMB remains exceptionally uncommon, occurring in only 1%–2% of cases. MSI, which reflects genomic hypermutability resulting from deficient DNA mismatch repair, is another established predictive biomarker for ICI therapy. MSI-high (MSI-H) status is strongly associated with the clinical benefits of ICIs. Similar to high TMB, MSI-H is exceedingly rare in PDAC, with a reported prevalence of <1%. Despite their low frequency, both TMB and MSI remain clinically significant because their identification can directly influence therapeutic decision-making in selected patients.
KRAS mutation subtypes have recently received increasing attention because of their potential biological and clinical implications in PDAC. Among the identified variants, G12D is the most prevalent, followed by G12V, and G12R. Except for KRAS G12C, which can be targeted with emerging inhibitors, therapeutic approaches for most KRAS alterations remain challenging. Nonetheless, emerging evidence suggests that individual KRAS subtypes have distinct prognostic and therapeutic implications. Notably, several studies have reported that tumors harboring G12R mutations exhibit more favorable clinical behavior, with improved treatment outcomes and slower progression of nodal or distant metastases, than other KRAS subtypes.34,35 These findings underscore the growing relevance of subtype-specific molecular characterization in PDAC.
Variant allele frequency (VAF) refers to the proportion of sequencing reads harboring a specific mutation relative to the total number of reads at that genomic locus. In PDAC, a higher KRAS VAF may indicate the dominance of the KRAS-mutated clone, and may also reflect increased tumor purity or a higher tumor fraction within the sampled specimen. Emerging evidence suggests that elevated VAF levels could be associated with adverse clinical outcomes, including worse prognosis and potential resistance to cytotoxic chemotherapy.36 However, these observations remain preliminary, and additional studies are needed to clarify the prognostic and therapeutic implications of VAF in PDAC. Although none of the included studies directly demonstrated improved oncologic outcomes from CGP performed on EUS-derived samples, a previous report demonstrated that patients receiving molecular profiling-matched therapies achieved superior survival compared to those receiving unmatched therapies or no biomarker-guided treatment. These findings support the active and broader utilization of EUS-TA-based CGP to facilitate precision oncology–driven treatment strategies in routine clinical practice.37 The major genomic alterations that characterize PDAC and their corresponding clinical implications are comprehensively outlined in Table 3.
The application of CGP using EUS-TA constitutes a technically feasible and clinically impactful approach for the contemporary management of PDAC. Although definitive evidence favoring either FNA or FNB remains limited, current data support the use of 22-G or larger needles when procedurally appropriate to enhance the likelihood of obtaining adequate specimens for sequencing. Beyond the identification of actionable alterations, emerging molecular metrics—including KRAS subtypes and VAF—offer additional dimensions for patient stratification and may enable further refinement of personalized therapeutic strategies. Continued efforts are required to optimize EUS-based sampling and specimen processing workflows and to advance approaches that enhance the effectiveness of NGS-guided treatment. Such progress will further consolidate the role of EUS-derived CGP as an essential component of precision oncology in PDAC.
Table 1.
Summary of prospective studies evaluating EUS-guided NGS performance in PDAC
Study Year No. patients Needle type Needle size Specimens No. of analyzed genes Sequencing success (%) KRAS detection (%) Actionable gene detection (%)
Valero et al.18 2016 19 FNA NR Fresh frozen 143 89.5 82.4 17.6
Dreyer et al.19 2019 41 FNB 22 FFPE tissue 409 100 96.2 34.6
Carrara et al.20 2021 33 FNB 22, 25 Fresh frozen 50 97.0 93.8 NR
Habib et al.21 2021 59 FNA 19 Fresh frozen 124 NR 85.7 NR
Semaan et al.22 2021 23 FNA 22, 25 Fresh smear 60 100 82.6 21.7
Hisada et al.12 2022 33 FNB 19, 22, 25 FFPE tissue 50 63.6 100 33.3
Yokoyama et al.23 2022 31 FNB 19, 22 Liquid-based cytology NR 100 80.0 NR
Redegalli et al.17 2023 76 FNA, FNB 22 Alcohol-fixed smear 47 88.2 87.3 15.0
Kamata et al.24 2023 50 FNB 19 Fresh frozen 409 93.6 84.0 NR

EUS, endoscopic ultrasound; NGS, next-generation sequencing; PDAC, pancreatic ductal adenocarcinoma; FNA, fine-needle aspiration; FNB, fine-needle biopsy; FFPE, formalin-fixed paraffin-embedded; NR, not-reported.

Table 2.
Endoscopic and technical determinants of NGS yield in EUS-guided tissue acquisition
Category Factors Impact on NGS yield Key notes for endoscopists
Needle type FNA vs. FNB Mixed evidence; no clear superiority FNB may provide larger cores and higher DNA in some studies; FNA may yield higher cellularity; overall difference not statistically significant.
Needle gauge 19-G/22-G/25-G Larger needles may increase tissue volume and DNA yield 22-G or larger is preferred when technically feasible; 19-G may be limited by stiffness and maneuverability, especially in pancreatic head.
No. of passes 2 vs. 3 2 vs. 3 passes showed no difference Two dedicated passes with 22-G Franseen-tip needle are sufficient for CGP; additional passes offer no added benefit.
Specimen format Cytology vs. histology No major difference in pooled sequencing success (>80%) Both formats acceptable; histology may help architecture-based analyses, cytology often has higher tumor cellularity.
Processing method FFPE, fresh-frozen, liquid-based No major difference in pooled sequencing success (>80%) Choose method based on institutional workflow; avoid delays or suboptimal fixation.
Platform requirements DNA input thresholds Major determinant of sequencing success Some platforms require >200 ng DNA (e.g., OncoGuide), while others can operate with ≥10 ng; choose platform compatible with expected tissue yield.

NGS, next-generation sequencing; EUS, endoscopic ultrasound; FNA, fine-needle aspiration; FNB, fine-needle biopsy; G, gauge; CGP, comprehensive genomic profiling; FFPE, formalin-fixed paraffin-embedded.

Table 3.
Key genomic alterations in PDAC and their clinical implications
Category Genomic finding Prevalence (%) Clinical implications
Major driver mutations KRAS 86 Core driver of PDAC; essential for molecular profiling
TP53 63 Tumor suppressor loss; adverse biology
SMAD4 22 Associated with metastatic patterns
CDKN2A 18 Cell-cycle dysregulation
Actionable mutations HRR pathway (BRCA1/2, PALB2, ATM) 10–12 Sensitivity to platinum agents or PARP inhibitors
BRAF V600E ~3 Targetable with BRAF-directed therapy
KRAS G12C ~2 Targetable with KRAS G12C inhibitors
Immunotherapy biomarkers High TMB (≥10 Mut/Mb) 1–2 Potential ICI response (rare in PDAC)
MSI-H <1 Strong predictor of ICI benefit (rare in PDAC)
KRAS mutation subtypes G12D, G12V, G12R G12R: associated with better outcomes & slower metastatic progression (emerging evidence)
Clonal metrics High KRAS VAF May reflect high tumor purity; associated with worse outcomes and chemo-resistance (emerging evidence)

PDAC, pancreatic ductal adenocarcinoma; HRR, homologous recombination repair; TMB, tumor mutational burden; MSI-H, microsatellite instability-high; ICI, immune checkpoint inhibitor; VAF, variant allele frequency.

  • 1. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817–1825.ArticlePubMed
  • 2. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–1703.ArticlePubMedPMC
  • 3. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381:317–327.ArticlePubMedPMC
  • 4. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1–10.Article
  • 5. Heinrich K, Fischer LE, De Toni EN, et al. Case of a patient with pancreatic cancer with sporadic microsatellite instability associated with a BRAF fusion achieving excellent response to immunotherapy. JCO Precis Oncol 2023;7:e2200650.ArticlePubMedPMC
  • 6. National Comprehensive Cancer Network (NCCN). Pancreatic adenocarcinoma, version 1. 2024. NCCN; 2024.
  • 7. van Riet PA, Larghi A, Attili F, et al. A multicenter randomized trial comparing a 25-gauge EUS fine-needle aspiration device with a 20-gauge EUS fine-needle biopsy device. Gastrointest Endosc 2019;89:329–339.ArticlePubMed
  • 8. Yoshinaga S, Itoi T, Yamao K, et al. Safety and efficacy of endoscopic ultrasound-guided fine needle aspiration for pancreatic masses: a prospective multicenter study. Dig Endosc 2020;32:114–126.ArticlePubMedPDF
  • 9. Fuccio L, Hassan C, Laterza L, et al. The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies. Gastrointest Endosc 2013;78:596–608.ArticlePubMed
  • 10. Ko SW, Jo IH, Yoon SB. Feasibility and clinical utility of endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling in pancreatic cancer: a systematic review and meta-analysis. Pancreatology 2025;25:89–97.ArticlePubMed
  • 11. Young G, Wang K, He J, et al. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol 2013;121:688–694.ArticlePubMed
  • 12. Hisada Y, Hijioka S, Ikeda G, et al. Proportion of unresectable pancreatic cancer specimens obtained by endoscopic ultrasound-guided tissue acquisition meeting the OncoGuide™ NCC Oncopanel System analysis suitability criteria: a single-arm, phase II clinical trial. J Gastroenterol 2022;57:990–998.ArticlePubMedPDF
  • 13. Ikeda G, Hijioka S, Nagashio Y, et al. Fine-needle biopsy with 19G needle is effective in combination with endoscopic ultrasound-guided tissue acquisition for genomic profiling of unresectable pancreatic cancer. Dig Endosc 2023;35:124–133.ArticlePubMedPDF
  • 14. Okuno N, Hara K, Mizuno N, et al. Clinical utility of endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling of pancreatic cancer. Clin Endosc 2023;56:221–228.ArticlePubMedPMCPDF
  • 15. Park JK, Lee JH, Noh DH, et al. Factors of endoscopic ultrasound-guided tissue acquisition for successful next-generation sequencing in pancreatic ductal adenocarcinoma. Gut Liver 2020;14:387–394.ArticlePubMedPMC
  • 16. Razzano D, Bouza SJ, Hernandez PV, et al. Comprehensive molecular profiling of pancreatic ductal adenocarcinoma in FNA, biopsy, and resection specimens. Cancer Cytopathol 2022;130:726–734.ArticlePubMed
  • 17. Redegalli M, Grassini G, Magliacane G, et al. Routine molecular profiling in both resectable and unresectable pancreatic adenocarcinoma: relevance of cytologic samples. Clin Gastroenterol Hepatol 2023;21:2825–2833.ArticlePubMed
  • 18. Valero V, Saunders TJ, He J, et al. Reliable detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing: implications for surgical management. Ann Surg 2016;263:153–161.ArticlePubMedPMC
  • 19. Dreyer SB, Jamieson NB, Evers L, et al. Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Chin Clin Oncol 2019;8:16.ArticlePubMed
  • 20. Carrara S, Soldà G, Di Leo M, et al. Side-by-side comparison of next-generation sequencing, cytology, and histology in diagnosing locally advanced pancreatic adenocarcinoma. Gastrointest Endosc 2021;93:597–604.ArticlePubMed
  • 21. Habib JR, Zhu Y, Yin L, et al. Reliable detection of somatic mutations for pancreatic cancer in endoscopic ultrasonography-guided fine needle aspirates with next-generation sequencing: implications from a prospective cohort study. J Gastrointest Surg 2021;25:3149–3159.ArticlePubMedPDF
  • 22. Semaan A, Bernard V, Lee JJ, et al. Defining the comprehensive genomic landscapes of pancreatic ductal adenocarcinoma using real-world endoscopic aspiration samples. Clin Cancer Res 2021;27:1082–1093.ArticlePubMedPDF
  • 23. Yokoyama S, Iwaya H, Akahane T, et al. Sequential evaluation of MUC promoter methylation using next-generation sequencing-based custom-made panels in liquid-based cytology specimens of pancreatic cancer. Diagn Cytopathol 2022;50:499–507.ArticlePubMed
  • 24. Kamata K, Takenaka M, Nishida N, et al. Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy. Int J Clin Oncol 2023;28:1511–1519.ArticlePubMedPDF
  • 25. Elhanafi S, Mahmud N, Vergara N, et al. Comparison of endoscopic ultrasound tissue acquisition methods for genomic analysis of pancreatic cancer. J Gastroenterol Hepatol 2019;34:907–913.ArticlePubMedPDF
  • 26. Larson BK, Tuli R, Jamil LH, et al. Utility of endoscopic ultrasound-guided biopsy for next-generation sequencing of pancreatic exocrine malignancies. Pancreas 2018;47:990–995.ArticlePubMed
  • 27. Kandel P, Nassar A, Gomez V, et al. Comparison of endoscopic ultrasound-guided fine-needle biopsy versus fine-needle aspiration for genomic profiling and DNA yield in pancreatic cancer: a randomized crossover trial. Endoscopy 2021;53:376–382.ArticlePubMed
  • 28. Bang JY, Jhala N, Seth A, et al. Standardisation of EUS-guided FNB technique for molecular profiling in pancreatic cancer: results of a randomised trial. Gut 2023;72:1255–1257.ArticlePubMedPMC
  • 29. Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 2017;32:185–203.ArticlePubMedPMC
  • 30. Perkhofer L, Schmitt A, Romero Carrasco MC, et al. ATM deficiency generating genomic instability sensitizes pancreatic ductal adenocarcinoma cells to therapy-induced DNA damage. Cancer Res 2017;77:5576–5590.ArticlePubMedPDF
  • 31. Wang Z, He D, Chen C, et al. Vemurafenib combined with trametinib significantly benefits the survival of a patient with stage IV pancreatic ductal adenocarcinoma with BRAF V600E mutation: a case report. Front Oncol 2021;11:801320.ArticlePubMed
  • 32. Hong DS, Fakih MG, Strickler JH, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med 2020;383:1207–1217.ArticlePubMedPMC
  • 33. Singhi AD, George B, Greenbowe JR, et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology 2019;156:2242–2253.ArticlePubMed
  • 34. Norton C, Shaw MS, Rubnitz Z, et al. KRAS mutation status and treatment outcomes in patients with metastatic pancreatic adenocarcinoma. JAMA Netw Open 2025;8:e2453588.ArticlePubMedPMC
  • 35. McIntyre CA, Grimont A, Park J, et al. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Cancer Cell 2024;42:1614–1629.ArticlePubMedPMC
  • 36. Suzuki T, Masugi Y, Inoue Y, et al. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Cancer Sci 2022;113:3097–3109.ArticlePubMedPMCPDF
  • 37. Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol 2020;21:508–518.ArticlePMC

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Touch imprint cytology: a practical step toward standardized rapid on-site evaluation
      Seong Ji Choi
      Clinical Endoscopy.2026; 59(4): 587.     CrossRef

    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Endoscopic ultrasound-guided tissue acquisition as a gateway to precision oncology in pancreatic cancer: current evidence and evolving clinical utility
      Close
    • XML DownloadXML Download
    Related articles
    Endoscopic ultrasound-guided tissue acquisition as a gateway to precision oncology in pancreatic cancer: current evidence and evolving clinical utility
    Endoscopic ultrasound-guided tissue acquisition as a gateway to precision oncology in pancreatic cancer: current evidence and evolving clinical utility
    Study Year No. patients Needle type Needle size Specimens No. of analyzed genes Sequencing success (%) KRAS detection (%) Actionable gene detection (%)
    Valero et al.18 2016 19 FNA NR Fresh frozen 143 89.5 82.4 17.6
    Dreyer et al.19 2019 41 FNB 22 FFPE tissue 409 100 96.2 34.6
    Carrara et al.20 2021 33 FNB 22, 25 Fresh frozen 50 97.0 93.8 NR
    Habib et al.21 2021 59 FNA 19 Fresh frozen 124 NR 85.7 NR
    Semaan et al.22 2021 23 FNA 22, 25 Fresh smear 60 100 82.6 21.7
    Hisada et al.12 2022 33 FNB 19, 22, 25 FFPE tissue 50 63.6 100 33.3
    Yokoyama et al.23 2022 31 FNB 19, 22 Liquid-based cytology NR 100 80.0 NR
    Redegalli et al.17 2023 76 FNA, FNB 22 Alcohol-fixed smear 47 88.2 87.3 15.0
    Kamata et al.24 2023 50 FNB 19 Fresh frozen 409 93.6 84.0 NR
    Category Factors Impact on NGS yield Key notes for endoscopists
    Needle type FNA vs. FNB Mixed evidence; no clear superiority FNB may provide larger cores and higher DNA in some studies; FNA may yield higher cellularity; overall difference not statistically significant.
    Needle gauge 19-G/22-G/25-G Larger needles may increase tissue volume and DNA yield 22-G or larger is preferred when technically feasible; 19-G may be limited by stiffness and maneuverability, especially in pancreatic head.
    No. of passes 2 vs. 3 2 vs. 3 passes showed no difference Two dedicated passes with 22-G Franseen-tip needle are sufficient for CGP; additional passes offer no added benefit.
    Specimen format Cytology vs. histology No major difference in pooled sequencing success (>80%) Both formats acceptable; histology may help architecture-based analyses, cytology often has higher tumor cellularity.
    Processing method FFPE, fresh-frozen, liquid-based No major difference in pooled sequencing success (>80%) Choose method based on institutional workflow; avoid delays or suboptimal fixation.
    Platform requirements DNA input thresholds Major determinant of sequencing success Some platforms require >200 ng DNA (e.g., OncoGuide), while others can operate with ≥10 ng; choose platform compatible with expected tissue yield.
    Category Genomic finding Prevalence (%) Clinical implications
    Major driver mutations KRAS 86 Core driver of PDAC; essential for molecular profiling
    TP53 63 Tumor suppressor loss; adverse biology
    SMAD4 22 Associated with metastatic patterns
    CDKN2A 18 Cell-cycle dysregulation
    Actionable mutations HRR pathway (BRCA1/2, PALB2, ATM) 10–12 Sensitivity to platinum agents or PARP inhibitors
    BRAF V600E ~3 Targetable with BRAF-directed therapy
    KRAS G12C ~2 Targetable with KRAS G12C inhibitors
    Immunotherapy biomarkers High TMB (≥10 Mut/Mb) 1–2 Potential ICI response (rare in PDAC)
    MSI-H <1 Strong predictor of ICI benefit (rare in PDAC)
    KRAS mutation subtypes G12D, G12V, G12R G12R: associated with better outcomes & slower metastatic progression (emerging evidence)
    Clonal metrics High KRAS VAF May reflect high tumor purity; associated with worse outcomes and chemo-resistance (emerging evidence)
    Table 1. Summary of prospective studies evaluating EUS-guided NGS performance in PDAC

    EUS, endoscopic ultrasound; NGS, next-generation sequencing; PDAC, pancreatic ductal adenocarcinoma; FNA, fine-needle aspiration; FNB, fine-needle biopsy; FFPE, formalin-fixed paraffin-embedded; NR, not-reported.

    Table 2. Endoscopic and technical determinants of NGS yield in EUS-guided tissue acquisition

    NGS, next-generation sequencing; EUS, endoscopic ultrasound; FNA, fine-needle aspiration; FNB, fine-needle biopsy; G, gauge; CGP, comprehensive genomic profiling; FFPE, formalin-fixed paraffin-embedded.

    Table 3. Key genomic alterations in PDAC and their clinical implications

    PDAC, pancreatic ductal adenocarcinoma; HRR, homologous recombination repair; TMB, tumor mutational burden; MSI-H, microsatellite instability-high; ICI, immune checkpoint inhibitor; VAF, variant allele frequency.


    Clin Endosc : Clinical Endoscopy Twitter Facebook
    Close layer
    TOP